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Abstract 19 
 20 
Entecavir (ETV) and tenofovir (TFV) are essential nucleoside analogues in current hepatitis B 21 
virus (HBV) treatments. Since these drugs target the HBV polymerase that is localized within 22 
human hepatocytes, determining of their cellular uptake process is an important step in fully 23 
understanding their pharmacological actions. However, the human hepatic transporters 24 
responsible for their uptake have remained unidentified. Therefore, this study aimed at 25 
identifying the primary ETV and TFV uptake transporter(s) in human hepatocytes. In transport 26 
assays, temperature-sensitive ETV and TFV uptake by human hepatocytes were observed, and 27 
their uptake were strongly inhibited by bromosulfophthalein, which is an inhibitor of organic 28 
anion transporters/organic anion transporting polypeptides (OATs/OATPs). Given these results, 29 
ETV and TFV uptake activities in several human OAT/OATP expression systems were 30 
examined. The results showed that, among the transporters tested, only OAT2 possessed ETV 31 
transport activity. On the other hand, none of the transporters showed any TFV uptake activity. 32 
To summarize, our results identify that human OAT2 is an ETV transporter, thereby suggesting 33 
that it plays an important part in the mechanisms underlying ETV antiviral activity. Furthermore, 34 
although the hepatic TFV transporters remain unknown, our results have, at least, clarified that 35 
these two anti-HBV drugs have different hepatocyte entry routes. 36 
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1. Introduction 39 
 40 
 Entecavir (ETV) and tenofovir (TFV), which are essential nucleoside analogues in 41 
current chronic hepatitis B treatment (see Fig. s1 for their structures), have shown better clinical 42 
efficacy than the classical anti-hepatitis B virus (HBV) drugs. However, it is also true that their 43 
effectiveness levels are highly variable, depending on the patients, and that a number of patients 44 
(roughly 10 to 40% in 48-week treatment) do not receive sufficient levels of benefit from these 45 
antiviral drugs [1-3]. In addition, there are currently no established guidelines instructing 46 
clinicians as to which drugs should be administered first for naïve patients. Nevertheless, since 47 
strong suppression of HBV activity is critically important for the incident rate reduction of liver 48 
cancer development, efficacy improvements for ETV- and TFV-based therapy (e.g., through the 49 
development of a manipulated personalized therapy method) are urgent issues that need to be 50 
addressed. Toward this end, detailed characterization of the mechanisms underlying ETV and 51 
TFV pharmacological actions should provide fundamental information.  52 
 Both ETV and TFV are converted into ETV-triphosphate and TFV-diphosphate 53 
intracellularly, which then act as HBV polymerase inhibitors. Therefore, it is very likely that 54 
ETV or TFV uptake by hepatocytes is a prerequisite step prior to exerting their antiviral activity, 55 
and that certain transporters, due to their significant hydrophilic natures, facilitate this step. 56 
5 
 
However, the uptake of ETV or TFV by human hepatocytes has not been characterized. On the 57 
other hand, human organic anion transporter 1 (OAT1) and OAT3 have been identified as ETV 58 
or TFV uptake transporters [4,5], and it has also been reported recently that concentrative 59 
nucleoside transporter 2 (CNT2) and CNT3 can transport ETV [6]. While these transporters are 60 
abundantly expressed in the kidney, they are only expressed marginally, if at all, in the human 61 
liver.  62 
 In light of the above-mentioned background, in this study, we sought to identify key 63 
ETV and TFV uptake transporters in human hepatocytes.  64 
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2. Materials and Methods 65 
 66 
2.1. Transport assay using human primary hepatocytes 67 
 68 
Pooled human primary hepatocytes (5-donor) were purchased from BioreclamationIVT 69 
(Baltimore, MD, USA). The Ethics Committee of the Chiba University Graduate School of 70 
Pharmaceutical Sciences approved the use of human samples in this study. 71 
[3H]-ETV (American Radiolabeled Chemicals, St. Louis, MO, USA) or [3H]-TFV 72 
(Moravek Biochemicals, Brea, CA, USA) uptake by hepatocytes was measured using a previously 73 
described centrifugal filtration technique (see the supplemental information). Bromosulfophthalein 74 
(BSP 200 µM) (Sigma, St. Louis, MO, USA), which is an OAT/organic anion transporting 75 
polypeptide (OATP) inhibitor, and indomethacin (IDM 50 µM) (Sigma), which is an OAT2 76 
substrate/inhibitor, were used in our inhibition assays. All assays were performed at 37°C and 4°C, 77 
with the data calculated by subtracting the 4°C activity from that at 37°C. 78 
 79 
2.2. Preparation of transporter expression systems 80 
 81 
 The OAT2 cDNA (encoding 546 amino acids, NM_006672) and the organic cation 82 
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transporter 1 (OCT1) cDNA was cloned from human liver cDNA and subcloned into the 83 
pcDNA3.1/Neo(-) (Thermo Fisher Scientific, Waltham, MA USA). OAT2/pcDNA or 84 
OCT1/pcDNA was transfected into human embryonic kidney 293 (HEK293) cells (Human 85 
Science, Tokyo, Japan), and the cells stably expressing OAT2 or OCT1 at the highest level were 86 
isolated and termed OAT2/HEK or OCT1/HEK, respectively. 87 
 Na+-taurocholate cotransporting polypeptide (NTCP) expression plasmid was kindly 88 
provided by Dr. Watashi (The National Institute of Infectious Diseases, Tokyo, Japan). As above, 89 
the HEK293 cells stably expressing NTCP were developed (NTCP/HEK).  90 
Preparation of the HEK293 cells expressing OATP1B1, OATP1B3, or OATP2B1, 91 
(which are OATP1B1/HEK, OATP1B3/HEK, and OATP2B1/HEK, respectively), the second 92 
segment of the proximal tubule (S2) cells expressing OAT7 (OAT7/S2), and their control cells 93 
(Mock/HEK and Mock/S2) were reported previously (see the supplemental information).  94 
  95 
2.3. Transport assay using transporter expression systems 96 
 97 
 Uptake studies using transporter expression systems were conducted according to the 98 
method described previously (see the supplemental information). Transporter activities of each 99 
system were validated using authentic substrates and inhibitors as shown in the figure legend. 100 
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The ETV and TFV uptake incubation times for each transporter were set at the same values 101 
employed for classical substrate uptake.  102 
 103 
2.4. Other 104 
 105 
Please see the supplemental information for detailed materials and methods, including 106 
their references.  107 
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3. Results and discussion 108 
 109 
 Considering that ETV and TFV are nucleoside analogues, it is possible that they might 110 
be substrates for equilibrative nucleoside transporters (ENTs). Therefore, we first examined this 111 
possibility using HepG2 cells, where ENTs are functionally expressed. However, the results 112 
showed that neither ETV nor TFV were taken up by ENTs (Fig. s1), thus indicating that other 113 
uptake systems are involved in their uptake by human hepatocytes. 114 
 It has also been reported that several members of OATP and OAT families are 115 
abundantly expressed in human hepatocytes, and that they facilitate the uptake of various drugs 116 
into the hepatocytes by taking advantage of their broad substrate specificities [7]. To clarify 117 
whether such organic anion transporters are involved in ETV and TFV uptake, transport assays 118 
using pooled (5-donor) human hepatocytes were carried out (Fig. 1). The results showed that 119 
temperature-sensitive ETV and TFV uptake activities were clearly observed, and that these 120 
activities were strongly repressed by BSP.  121 
 In order to identify the key transporters that contribute significantly to hepatic ETV 122 
uptake, we prepared in vitro expression systems of the primary BSP-sensitive hepatic uptake 123 
transporters OATP1B1, OATP1B3, OATP2B1, OAT2, OAT7, and NTCP. Additionally, we 124 
prepared OCT1/HEK to further test its possible involvement in ETV uptake. When ETV uptake 125 
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was examined using these systems, the results clearly showed that while all transporter activities 126 
were validated (Fig. 2A), only OAT2 demonstrated remarkable ETV transport activity (Fig. 2B 127 
and Fig. s2). Then, the kinetic analysis of OAT2-mediated ETV uptake was also performed 128 
using OAT2/HEK. As the results, the transport pathway appeared to be the low affinity system, 129 
where apparent Km and Vmax values were estimated to be 150 ± 44 (µM) and 1,559 ± 276 130 
(pmol/mg protein/min), respectively (Fig. s2). In order to evaluate contribution of OAT2 to ETV 131 
uptake by human hepatocytes, we examined inhibitory effects of IDM on the hepatic ETV 132 
uptake. The results showed that, in the presence of IDM, the hepatocyte ETV uptake level 133 
decreased to less than 35% of that obtained in the absence of IDM (Fig. s3). This is in 134 
agreement with the report describing involvement of rat Oat2 in ETV uptake by rat liver [8] 135 
 Therefore, even though another unidentified transporter may also be involved, the 136 
circumstantial evidence in our results suggests that OAT2 plays an important role in hepatic 137 
ETV uptake by human hepatocytes. This notion is imminently reasonable when considering that 138 
the target cell type of ETV is hepatocyte, and that OAT2 is known as a liver-enriched transporter 139 
in the OAT family. Since it has been reported that drugs containing a guanine moiety (such as 140 
acyclovir and ganciclovir [9]) are substrate of OAT2, presumably OAT2 transports ETV through 141 
a similar substrate recognition site.  142 
 In addition, it should be briefly mentioned that, while rat Oct1 has been considered to 143 
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be involved in ETV uptake by rat liver [8], our results suggest that human OCT1 is unlikely to 144 
contribute to hepatic ETV uptake significantly. The reason for this apparent difference is 145 
currently unknown, but this might result from species difference.  146 
 Having identified OAT2 as an ETV transporter, the next likely question is whether the 147 
functional variability of OAT2 is directly related to ETV’s pharmacological action. Previously, 148 
we have shown that the efficacy of ribavirin, which is an anti-hepatitis C virus nucleoside 149 
analogue, is clearly dependent on its ENT1-mediated uptake [10]. Therefore, a similar narrative 150 
is suspected in the case of ETV, and it is worth investigating this possibility in future studies. 151 
 On the other hand, we also attempted to identify hepatic TFV uptake transporters 152 
utilizing the same set of transporter expression systems, but none of the transporters showed 153 
TFV uptake activity. Since OAT1-mediated TFV uptake was clearly observed (Fig. s4) and that 154 
each expression system shows clear classical substrate uptake activity (Fig. 2A) (please also see 155 
Fig. s5B, where OAT2 expression level in OAT2/HEK293 appears to be comparable to that of 156 
the human primary hepatocytes used in this study), the results were unlikely due to 157 
inappropriate experimental conditions or considerable insufficiency of the transporter 158 
expression levels. In addition, TFV concentration used in this study (1 μM) is similar to the Cmax 159 
after taking a single dose of 300 mg of tenofovir disoproxil fumarate (0.73-1.03 μM, TENOZET 160 
Interview Form). Therefore, although the possibility that OAT2 and the other transporters might 161 
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show TFV uptake activity at its higher concentrations cannot be fully excluded, their TFV 162 
uptake levels in clinical settings are assumed to be very low, if any. 163 
Nevertheless, even though the hepatic TFV transporters remain unclear, our results 164 
provide at least one important finding, which is that ETV and TFV have distinctly different 165 
hepatocyte entry routes. This also indicates that while ETV and TFV share the structural 166 
similarities to target HBV polymerase, there is a clear difference between the molecular steps 167 
regarding their pharmacological actions. Therefore, clarification of the different hepatocyte 168 
entry routes between these two anti-HBV drugs may be one of the basic findings contributing to 169 
the development of a drug selection methodology in clinical settings, and the identification of 170 
the hepatic TFV uptake transporter will remain an important challenge in our future study. 171 
To summarize, our results clearly show that OAT2 is a key ETV uptake transporter in 172 
human hepatocytes, and that ETV and TFV are distinctly different in terms of their entry routes 173 
into human hepatocytes. Since detailed characterization of the anti-HBV drug uptake profile 174 
into hepatocytes will provide various clues that contribute to treatment improvements, 175 
continuous research efforts, including additional attempts to identify hepatic TFV transporters, 176 
will be necessary.   177 
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Figure legends 223 
 224 
Fig. 1. ETV and TFV uptake by primary human hepatocytes. 225 
 226 
ETV (1 μM, left) and TFV (1 μM, right) uptake by pooled (5-donor) primary human 227 
hepatocytes were examined using suspension transport assays. BSP (200 μM) was used as an 228 
inhibitor of drug transporters. The assays were also performed at 4°C, and each data was 229 
calculated by subtracting the 4°C activity from that at 37°C. The experiments were repeated five 230 
times, each performed in duplicate, and the value represents the mean ± S.D. N.D., not detected.  231 
 232 
Fig. 2. Examination of ETV and TFV uptake activities of hepatic drug uptake 233 
transporters. 234 
 235 
A, Functional validation of each transporter expression system was conducted. Substrates are: 236 
E2G (100 nM) for OATP1B1, CCK-8 (10 nM) for OATP1B3, E1S (50 μM and 1 μM) for 237 
OATP2B1 and OAT7, respectively, cGMP (2 μM) for OAT2, MPP+ (10 μM) for OCT1, and 238 
TCA (1 μM) for NTCP, while inhibitors are: RIF (10 μM) for OATP1B1, BSP (100 μM) for 239 
OATP1B3, OATP2B1 and OAT7, IDM (100 μM) for OAT2, TEA (20 mM) for OCT1, and CA 240 
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(100 μM) for NTCP. Since transporter activities of the OATP1B1, OATP1B3, OATP2B1 241 
expression systems have been tested in previous reports (please see supplemental file), 242 
experiments were conducted twice for confirmation, with the results shown as the mean values. 243 
For OAT2, OCT1, OAT7, and NTCP expression systems, validation experiments were 244 
performed three times, each performed in duplicate. The results are shown as the mean ± S.D.  245 
B and C, ETV (1 μM) and TFV (1 μM) uptake were examined using the same systems and 246 
inhibitors. Each value is the mean ± S.D. of transport activity for three independent experiments, 247 
each performed in duplicate. 248 
Supplemental materials and methods 1 
 2 
Materials 3 
 4 
 [3H]-labelled entecavir (ETV), [3H]-labelled estradiol-17β-D-glucuronide (E2G), 5 
[3H]-labelled taurocholic acid (TCA), and [3H]-labelled 1-methyl-4-phenylpyridinium (MPP+) were 6 
purchased from American Radiolabeled Chemicals (St. Louis, MO, USA). [3H]-labelled 7 
estrone-3-sulfate (E1S) and [3H]-labelled cholecystokinin octapeptide sulfated (CCK-8) were 8 
obtained from PerkinElmer Life Science (Boston, MA, USA). [3H]-labelled cyclic GMP (cGMP), 9 
[3H]-labelled tenofovir (TFV), and [3H]-labelled adenosine (Ado) were purchased from Moravek 10 
Biochemicals (Brea, CA, USA). 11 
 ETV and TFV were purchased from Toronto Research Chemicals (Toronto, ON, Canada). 12 
E2G, E1S, cGMP, bromosulfophthalein (BSP), indomethacin (IDM), TCA, cholic acid (CA), Ado, 13 
nitrobenzylmercaptopurine riboside (NBMPR), MPP+, tetraethylammonium (TEA), and G418 14 
disulfate were purchased from Sigma (St. Louis, MO, USA). CCK-8, Rifampicin (RIF), and Zeocin 15 
were purchased from Peptide Institute (Osaka, Japan), Wako (Osaka, Japan), and Invivogen (San 16 
Diego, CA, USA), respectively.  17 
 The pcDNA3.1/Neo(-), the pcDNA3.1/Zeo(-), and insulin-transferrin-selenium 18 
supplement was provided by Thermo Fisher Scientific (Waltham, MA USA). Human embryonic 19 
kidney 293 (HEK293) cells and human hepatoma HepG2 cells were obtained from the Human 20 
Science (Tokyo, Japan) and the Institute of Development, Aging and Cancer, Tohoku University 21 
(Sendai, Japan), respectively. Dulbecco's Modified Eagle's Medium (DMEM), DMEM/Ham’s 22 
F-12, and recombinant human epidermal growth factor (Lonza, Walkersville, MD, USA) were 23 
obtained from Wako (Osaka, Japan).  24 
 25 
Transport assays using hepatocytes 26 
 27 
Pooled human hepatocytes (5-donor) were purchased from BioreclamationIVT (Baltimore, 28 
MD, USA). The Ethics Committee of the Chiba University Graduate School of Pharmaceutical 29 
Sciences approved the use of human samples in this study. 30 
[3H]-ETV or [3H]-TFV uptake by hepatocytes was measured using a previously described 31 
centrifugal filtration technique [1]. BSP (200 µM, an organic anion transporter (OAT)/organic anion 32 
transporting polypeptide [OATP] inhibitor) and IDM (50 µM, an OAT2 substrate/inhibitor) were 33 
used in our inhibition assays. All assays were performed at 37°C and 4°C, with the data calculated 34 
by subtracting the 4°C activity from that at 37°C. 35 
 36 
Preparation of transporter expression systems 37 
 38 
The OAT2 cDNA (encoding 546 amino acids, NM_006672) or the OCT1 cDNA 39 
(NM_003057) was cloned from human liver cDNA using polymerase chain reaction (PCR) with 40 
primers, as shown in Table S1. Subsequently, OAT2 or OCT1 cDNA was subcloned into the 41 
pcDNA3.1/Neo(-). Similarly, OAT1 cDNA (NM_153276) was cloned from human kidney 42 
cDNA (Table S1), and transferred into pcDNA3.1/Neo(-). Their cDNA sequences were 43 
confirmed by DNA sequencing.  44 
HEK293 cells were cultured in DMEM supplemented with 10% fetal bovine serum 45 
and antibiotics in 5% CO2 at 37ºC. OAT2/pcDNA or OCT1/pcDNA was transfected into 46 
HEK293 cells, after which the cells stably expressing OAT2 or OCT1 were selected by G418 47 
(400 µg/mL). The clonal cell line stably expressing OAT2 or OCT1 at the highest level was 48 
isolated and termed OAT2/HEK or OCT1/HEK, respectively. In addition to their functions, 49 
OAT2 or OCT1 mRNA expression in the cells was confirmed by reverse-transcription PCR 50 
(RT-PCR) using the primers shown in Table S1, the result of which was shown in Fig. s5. 51 
Na+-taurocholate cotransporting polypeptide (NTCP) expression plasmid 52 
(NTCP/pEF4) was kindly provided by Dr. Koichi Watashi of the National Institute of Infectious 53 
Diseases, Tokyo, Japan. As above, NTCP/pEF4 was transfected into HEK293 cells, after which 54 
the cells stably expressing NTCP were selected by Zeocin (300 µg/mL). The resultant cells 55 
stably expressing NTCP (NTCP/HEK) were used hereafter. As with the case of OAT2, NTCP 56 
mRNA expression was confirmed by RT-PCR (Fig. s5). 57 
Preparation procedures of the HEK293 cells expressing OATP1B1, OATP1B3, or 58 
OATP2B1 (which are OATP1B1/HEK, OATP1B3/HEK, or OATP2B1/HEK, respectively), as 59 
well as those for their control cells (pcDNA3.1/Neo(-) or pcDNA3.1/Zeo(-) empty 60 
vector-transfected cells, Mock/HEK), were reported previously [2-4]. Likewise, the second 61 
segment of the proximal tubule (S2) cells expressing OAT7 (OAT7/S2), as well as those for 62 
their control cells (pcDNA3.1/Neo(+) empty vector-transfected cells, Mock/S2), was described 63 
previously [5].  64 
S2 cells were cultured in DMEM/Ham’s F-12 supplemented with 5% fetal bovine 65 
serum, insulin-transferrin-selenium supplement, recombinant human epidermal growth factor, 66 
G418 (400 µg/mL), and antibiotics in 5% CO2 at 33ºC. 67 
 68 
Quantitative real-time PCR (qPCR) 69 
 70 
 qPCR was performed using the previously described SYBR green-based method [6] to 71 
determine the OAT2 mRNA expression levels in OAT2/HEK and pooled human hepatocytes 72 
used in this study (Fig. s5). The primers used for qPCR are described in Table S1, and the 73 
amplification efficiency of each PCR was confirmed to be close to one. Data was calculated 74 
using the delta-delta-CT method, where GAPDH was used as a control.  75 
 76 
Table S1. Primer sequences used in this study 77 
Experiments Direction Primer sequences  
OAT1 cDNA cloning Sense 5’-ACA GAC AGA GGT CCT GGG A-3’ 
Anti-sense 5’-CAC ACT TGG GTC ACC ATT T-3’ 
OAT2 cDNA cloning Sense 5’-TGA AGC ATT TGG TGG GTG AGC AGC AT-3’ 
Anti-sense 5’-TGG ATG AGC AGA GGG AGC GGG TAC TG-3’ 
OCT1 cDNA cloninga Sense 5’-AAG AAT TCG CCA TCA TGC CCA CCG TGG 
ATG-3’ 
Anti-sense 5’-AAG GAT CCT CAG GTG CCC GAG GGT TCT 
GAG GTT-3’ 
OAT2 RT-PCR Sense 5’-CTA TCC CCA GGC TCT CCC CAA CAC-3’ 
Anti-sense 5’-TGA GCC AGT AAG GGT GCG GGT GA-3’ 
OCT1 RT-PCR Sense 5’-GAA CCT CTA CCT GGA TTT CC-3’ 
Anti-sense 5’-CCA GTG CAG GTC AGG TGA GAT AAA A-3’ 
NTCP RT-PCR Sense 5’-TTG TTC TTC ATC ATG CTC TCG C-3’ 
Anti-sense 5’-CCA AGG GCA CAG AAG GTG GAG C-3’ 
GAPDH RT-PCR Sense 5’-TGC ACC ACC AAC TGC TTA-3’ 
Anti-sense 5’-GGA TGC AGG GAT GAT GTT C-3’ 
OAT2 qPCR Sense 5’-TAG CTG TCA CCC TGC CTT GT-3’ 
Anti-sense 5’-CAT GGC CTT GGG TCA GAA-3’ 
GAPDH qPCR Sense 5’-TGC ACC ACC AAC TGC TTA-3’ 
Anti-sense 5’-GGA TGC AGG GAT GAT GTT C-3’ 
a, the EcoRI site and the BamHI site are included in the sense and the antisense primer, 78 
respectively. 79 
 80 
Transport assay 81 
 82 
 The transporter activity level of each expression system was determined based 83 
essentially on methods described previously [2-4]. Substrates and inhibitors are summarized in 84 
Table S2. The vehicle was sterile water or dimethylsulfoxide. The ETV and TFV uptake 85 
incubation times for each transporter were set at the same values employed for classical 86 
substrate uptake, which are: 3 min for OATP1B1, 5 min for OATP1B3, 3 min for OATP2B1, 1.5 87 
min for OAT2, 2 min for OAT7, 1.5 min for OCT1, and 1.5 min for NTCP.  88 
 In kinetic parameter analysis, transporter activity levels were calculated by subtracting 89 
the value obtained from mock-cells from the value obtained from transporter-expressed cells. 90 
ETV concentrations used in this analysis were 0.5, 1, 10, 50, 100, and 200 μM. Transport 91 
kinetics were first evaluated using an Eadie-Hofstee plot, and then apparent Km and Vmax values 92 
were estimated by a computer program (DeltaGraph Ver 4.5, SPSS Inc., Chicago, IL), which is 93 
designed for non-linear regression analysis. 94 
 Using the same experimental procedures, equilibrative nucleoside 95 
transporter-mediated ETV or TFV uptake was examined using HepG2 cells. Adenosine (10 μM) 96 
and NBMPR (100 μM) were used as the model substrate and inhibitor, respectively. Incubation time 97 
was set at 1 min. HepG2 cells were cultured using the same method as that used for the HEK293 98 
cells. 99 
 OAT1-mediated TFV uptake was examined using the transient expression assay. The 100 
OAT1 expression plasmid was transfected with HEK293 cells. The procedures used for the TFV 101 
transport assay was the same as those employed for other transporters.  102 
 103 
Table S2. Summary of transporter substrates and inhibitors used in this study 104 
Transporter Substrate (concentration) Inhibitor (concentration) 
OATP1B1 Estradiol-17β-D-glucuronide (100 nM) Rifampicin (10 μM) 
OATP1B3 Cholecystokinin Octapeptide, sulfated (10 nM) Bromosulfophthalein (100 μM) 
OATP2B1 Estrone-3-sulfate (50 μM) Bromosulfophthalein (100 μM) 
OAT1 Tenofovir (1 μM) Not used 
OAT2 cyclic GMP (2 μM) Indomethacin (100 μM) 
OAT7 Estrone-3-sulfate (1 μM) Bromosulfophthalein (100 μM) 
OCT1 1-methyl-4-phenylpyridinium (10 μM) Tetraethylammonium (20 mM) 
NTCP Taurocholic acid (1 μM) Cholic acid (100 μM) 
All Entecavir (1 μM) Either one of the above 
All Tenofovir (1 μM) Either one of the above 
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Fig. s1. Examination of ENT-mediated ETV or TFV uptake in HepG2 cells.
The ETV or TFV uptake activities of ENTs were examined using HepG2 cells. ENTs
functions were confirmed using adenosine (10 μM) as a typical substrate. NBMPR (100
μM) is an ENTs inhibitor. Similarly, ENT-mediated ETV and TFV uptake by HepG2 cells
was tested. Each value is the mean ± S.D. of transport activity for three independent
experiments, each performed in duplicate.
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Fig. s2. Additional characterization of OAT2-mediated ETV uptake in
OAT2/HEK.
A, ETV uptake by OAT2/HEK was inhibited by BSP (100 μM). Each value is the
mean ± S.D. of transport activity for three independent experiments, each
performed in duplicate.
B, Kinetic parameters of OAT2-mediated ETV uptake were estimated using
OAT2/HEK. Substrate concentrations were 0.5, 1, 10, 50, 100, and 200 μM. The
assays were also performed using Mock/HEK, and each data was calculated by
subtracting the activity obtained by Mock/HEK from that of OAT2/HEK. Each value
is the mean ± S.D. of transport activity for three independent experiments, each
performed in duplicate. Transport kinetics were first evaluated using an Eadie-
Hofstee plot [y = -193.17x + 1775.8, R² = 0.902], and then apparent Km and Vmax
values were estimated by a computer program (DeltaGraph Ver 4.5).
A B
0
2
4
6
8
10
12
14
16
18
E
T
V
 u
p
ta
k
e
 (
p
m
o
l/
m
g
 p
ro
te
in
/m
in
)
OAT2
Mock
/HEK OAT2/HEK
BSP
0
200
400
600
800
1000
0 2 4 6 8 10
V
V/[S]
IDM
ETV
R
e
la
ti
v
e
 u
p
ta
k
e
 a
c
ti
v
it
y
 (
%
)
Fig. s3. Inhibitory effects of indomethacin on
ETV uptake by primary human hepatocytes.
ETV (1 μM) uptake by pooled (5-donor) primary
human hepatocytes were examined using
suspension transport assays in the presence or
absence of indomethacin (IDM, 50 μM), which is an
OAT2 substrate/inhibitor. The assays were also
performed at 4ºC, and each data was calculated by
subtracting the 4ºC activity from that at 37ºC. The
value are expressed as relative uptake levels and
represents the mean ± S.D. The experiments were
repeated four times, each performed in duplicate.
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Fig. s4. Validation of TFV uptake by OAT1.
TFV uptake activity was examined using HEK293 cells
transiently expressing OAT1 (OAT1/HEK) and those
transfected with empty vector (Mock/HEK). Each value is
the mean± S.D. of transport activity for three independent
experiments, each performed in duplicate.
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Fig. s5. Confirmation of transporter mRNA expression in HEK293
expression systems developed in this study.
A, Total RNA were isolated from OAT2/HEK, OCT1/HEK, NTCP/HEK and
Mock/HEK, and their cDNA were synthesized. RT-PCR was performed to detect
OAT2 mRNA, OCT1 mRNA or NTCP mRNA. GAPDH mRNA was used as an
internal control. NTC, non-template control. The representative results from three
independent experiments are shown.
B, The OAT2 mRNA expression level in OAT2/HEK was compared with that of
pooled (5-donor) primary human hepatocytes by quantitative real-time PCR.
GAPDH mRNA was used as an internal control. The value are expressed as
relative mRNA levels and represents the mean ± S.D. The experiments were
repeated three times, each performed in duplicate.
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